About: Pavinetant

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Pavinetant (INN, USAN; developmental code names MLE-4901, AZD-4901, AZ-12472520, AZD-2624), is a small-molecule, orally active, selective neurokinin-3 (NK3) receptor antagonist which was under development by AstraZeneca and Millendo Therapeutics for the treatment of hot flashes and polycystic ovary syndrome (PCOS). It was also under investigation for the treatment of schizophrenia, but development was discontinued for this indication due to lack of effectiveness. In November 2017, development of the medication for hot flashes and PCOS was also terminated after its developer assessed the clinical risks and benefits.

Property Value
dbo:abstract
  • Pavinetant (INN, USAN; developmental code names MLE-4901, AZD-4901, AZ-12472520, AZD-2624), is a small-molecule, orally active, selective neurokinin-3 (NK3) receptor antagonist which was under development by AstraZeneca and Millendo Therapeutics for the treatment of hot flashes and polycystic ovary syndrome (PCOS). It was also under investigation for the treatment of schizophrenia, but development was discontinued for this indication due to lack of effectiveness. In November 2017, development of the medication for hot flashes and PCOS was also terminated after its developer assessed the clinical risks and benefits. (en)
dbo:casNumber
  • 941690-55-7
dbo:chEBI
  • 140478
dbo:chEMBL
  • 3545233
dbo:fdaUniiCode
  • 3U471ZVC5K
dbo:kegg
  • D11345
dbo:pubchem
  • 23649245
dbo:thumbnail
dbo:wikiPageExternalLink
dbo:wikiPageID
  • 53980347 (xsd:integer)
dbo:wikiPageLength
  • 4182 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1045199915 (xsd:integer)
dbo:wikiPageWikiLink
dbp:c
  • 26 (xsd:integer)
dbp:casNumber
  • 941690 (xsd:integer)
dbp:chebi
  • 140478 (xsd:integer)
dbp:chembl
  • 3545233 (xsd:integer)
dbp:chemspiderid
  • 28189763 (xsd:integer)
dbp:h
  • 25 (xsd:integer)
dbp:iupacName
  • 3 (xsd:integer)
dbp:kegg
  • D11345 (en)
dbp:n
  • 3 (xsd:integer)
dbp:o
  • 3 (xsd:integer)
dbp:pubchem
  • 23649245 (xsd:integer)
dbp:routesOfAdministration
dbp:s
  • 1 (xsd:integer)
dbp:smiles
  • CC[C@@H]NCC2=CNSC (en)
dbp:stdinchi
  • 1 (xsd:integer)
dbp:stdinchikey
  • QYTBBBAHNIWFOD-NRFANRHFSA-N (en)
dbp:synonyms
  • MLE-4901; AZD-4901; AZD-2624; AZ-12472520 (en)
dbp:unii
  • 3 (xsd:integer)
dbp:width
  • 225 (xsd:integer)
dbp:wikiPageUsesTemplate
dcterms:subject
rdf:type
rdfs:comment
  • Pavinetant (INN, USAN; developmental code names MLE-4901, AZD-4901, AZ-12472520, AZD-2624), is a small-molecule, orally active, selective neurokinin-3 (NK3) receptor antagonist which was under development by AstraZeneca and Millendo Therapeutics for the treatment of hot flashes and polycystic ovary syndrome (PCOS). It was also under investigation for the treatment of schizophrenia, but development was discontinued for this indication due to lack of effectiveness. In November 2017, development of the medication for hot flashes and PCOS was also terminated after its developer assessed the clinical risks and benefits. (en)
rdfs:label
  • Pavinetant (en)
owl:sameAs
prov:wasDerivedFrom
foaf:depiction
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License